YAKHAK HOEJI

Table. 5.

Table 5 Disproportionality and sensitivity analysis of adverse drug reactions related to weight loss and lipid-lowering effects of tenofovir disoproxil fumarate

	KAERS				FAERS
	case	%	ROR	95%CI	case	%	ROR	95%CI
Lipid-lowering AE	0	-	-	-	2	0.00	0.2	0.1-0.7
Weight loss AE	19	0.17	1.3	0.9-1.8	51	0.04	0.3	0.2-0.4
ASSESSMENT
Lipid-lowering AE	0	-	-	-	0	-	0.0	-
Weight loss AE	0	-	-	-	39	0.04	0.3	0.2-0.3
DISEASE CODE
Lipid-lowering AE	0	-	-	-	0	-	-	-
Weight loss AE	2	0.17	2.0	0.7-6.0	3	0.04	1.3	0.4-3.7
YEAR<2017	YEAR<2016
Lipid-lowering AE	0	-	-	-	0	-	-	-
Weight loss AE	9	0.16	1.8	1.0-3.0	11	0.07	0.9	0.5-1.6
YEAR>2017	YEAR>2016
Lipid-lowering AE	0	-	-	-	2	0.00	0.2	0.0-0.7
Weight loss AE	9	0.19	1.1	0.7-1.7	40	0.04	0.3	0.2-0.4

Abbreviation: AE, Adverse event; CI, Confidence interval; FAERS, United States Food and Drug administration adverse events reporting system; KAERS, Korea adverse event reporting system; ROR, Reporting Odds Ratio.

Yakhak Hoeji 2024;68:362-70 https://doi.org/10.17480/psk.2024.68.5.362